Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Q2 Revenues Jump 38 Percent, Earnings Climb 48 Percent

NEW YORK, July 27 (GenomeWeb News) - Molecular Devices yesterday reported increased revenues and earnings for the second quarter of 2005.

 

Revenues for the quarter were $44.5 million, up 38 percent over last year's revenues for the same period, which were $32.2 million.

 

Research and development expenses rose to $6.3 million, from $4.7 million during the year-ago period.

 

The firm's net income rose to $3.7 million, or $.22 per share, a 48-percent increase over last year's $2.5 million, or $.17 per share.

 

As of June 30, Molecular Devices had $12.5 million in cash and cash equivalents.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.